Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 13:14:890512.
doi: 10.3389/fnagi.2022.890512. eCollection 2022.

Application of Neurotoxin-Induced Animal Models in the Study of Parkinson's Disease-Related Depression: Profile and Proposal

Affiliations
Review

Application of Neurotoxin-Induced Animal Models in the Study of Parkinson's Disease-Related Depression: Profile and Proposal

Ya-Kui Mou et al. Front Aging Neurosci. .

Abstract

Depression can be a non-motor symptom, a risk factor, and even a co-morbidity of Parkinson's disease (PD). In either case, depression seriously affects the quality of life of PD patients. Unfortunately, at present, a large number of clinical and basic studies focused on the pathophysiological mechanism of PD and the prevention and treatment of motor symptoms. Although there has been increasing attention to PD-related depression, it is difficult to achieve early detection and early intervention, because the clinical guidelines mostly refer to depression developed after or accompanied by motor impairments. Why is there such a dilemma? This is because there has been no suitable preclinical animal model for studying the relationship between depression and PD, and the assessment of depressive behavior in PD preclinical models is as well a very challenging task since it is not free from the confounding from the motor impairment. As a common method to simulate PD symptoms, neurotoxin-induced PD models have been widely used. Studies have found that neurotoxin-induced PD model animals could exhibit depression-like behaviors, which sometimes manifested earlier than motor impairments. Therefore, there have been attempts to establish the PD-related depression model by neurotoxin induction. However, due to a lack of unified protocol, the reported results were diverse. For the purpose of further promoting the improvement and optimization of the animal models and the study of PD-related depression, we reviewed the establishment and evaluation strategies of the current animal models of PD-related depression based on both the existing literature and our own research experience, and discussed the possible mechanism and interventions, in order to provide a reference for future research in this area.

Keywords: Parkinson’s disease; animal model; depression; neurotoxin; non-motor symptoms.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The model diagram of the relationship between depression and PD. In case 1, depression is a risk factor for PD; in case 2, depression is a non-motor symptom of PD, and there are three sub cases, that is, it appears before motor symptoms as a prodromal symptom: (a) occurs simultaneously with motor symptoms; (b) and appears after motor symptoms; and (c) in case 3, it appears as an independent disease and comorbidity of PD.

References

    1. Airavaara M., Parkkinen I., Konovalova J., Albert K., Chmielarz P., Domanskyi A. (2020). Back and to the future: from neurotoxin-induced to human Parkinson’s disease models. Curr. Protoc. Neurosci. 91:e88. 10.1002/cpns.88 - DOI - PubMed
    1. Alzoubi K. H., Mokhemer E., Abuirmeileh A. N. (2018). Beneficial effect of etazolate on depression-like behavior and, learning and memory impairment in a model of Parkinson’s disease. Behav. Brain Res. 350, 109–115. 10.1016/j.bbr.2018.05.004 - DOI - PubMed
    1. Antunes M. S., Goes A. T., Boeira S. P., Prigol M., Jesse C. R. (2014). Protective effect of hesperidin in a model of Parkinson’s disease induced by 6-hydroxydopamine in aged mice. Nutrition 30, 1415–1422. 10.1016/j.nut.2014.03.024 - DOI - PubMed
    1. Barbiero J. K., Santiago R. M., Persike D. S., da Silva Fernandes M. J., Tonin F. S., da Cunha C., et al. (2014). Neuroprotective effects of peroxisome proliferator-activated receptor alpha and gamma agonists in model of parkinsonism induced by intranigral 1-methyl-4-phenyl-1,2,3,6-tetrahyropyridine. Behav. Brain Res. 274, 390–399. 10.1016/j.bbr.2014.08.014 - DOI - PubMed
    1. Bastías-Candia S., Zolezzi J. M., Inestrosa N. C. (2019). Revisiting the paraquat-induced sporadic Parkinson’s disease-like model. Mol. Neurobiol. 56, 1044–1055. 10.1007/s12035-018-1148-z - DOI - PubMed